Today: 21 May 2026
D-Wave Quantum stock slides 4% into weekend — what QBTS traders watch before Monday
11 January 2026
2 mins read

D-Wave Quantum stock slides 4% into weekend — what QBTS traders watch before Monday

New York, Jan 11, 2026, 07:08 EST — Market closed

D-Wave Quantum Inc. shares closed Friday around 4% lower at $28.11, wrapping up a volatile week for the quantum computing firm. The stock fluctuated between $31.14 and $28.07 during the session, with roughly 46.7 million shares traded. Investors will face a fresh deal timetable come Monday.

The pullback is significant because D-Wave’s strategy is shifting beyond just marketing quantum services. The firm now aims to expand its focus from “quantum annealing”—a niche method typically applied to optimization problems—toward gate-model machines, the architecture most competitors target for a wider range of computing applications.

That change raises immediate concerns investors hate: the dilution tied to the stock portion of a major deal, and the timeline for turning lab breakthroughs into market-ready products. Activity in options and analyst commentary points to expectations of volatility, not a slow, steady climb.

Rosenblatt Securities analyst John McPeake bumped his price target on D-Wave to $43 from $40 over the last two days, citing the company’s latest technical update and its upcoming acquisition of Quantum Circuits, TipRanks reports.

A securities filing detailed the deal’s structure that investors are now dissecting. D-Wave will pay $550 million for Quantum Circuits — splitting $250 million in cash and $300 million in common stock. The share count is based on a 10-day volume-weighted average price, or VWAP, but with a “collar” setting a floor at $22.30 and a cap at $39.03. According to the filing, the deal can be called off if it hasn’t closed by April 6, 2026. SEC

D-Wave announced the combined company aims to launch superconducting gate-model systems by 2026. “With this acquisition, we believe that D-Wave has unequivocally cemented its position” in superconducting quantum computing, CEO Alan Baratz said. Quantum Circuits co-founder Rob Schoelkopf added the deal should “significantly speed up the timeline” for achieving fault-tolerant, error-corrected quantum computing. D-Wave Quantum

Just days ago, D-Wave announced it had achieved “on-chip cryogenic control” for gate-model qubits — or quantum bits — a move designed to slash the wiring and hardware demands as these systems grow. “Without on-chip control and multiplexing, useful gate-model quantum computers require an impractically large amount of wiring,” said chief development officer Trevor Lanting. SEC

The wider quantum-computing sector cooled off heading into the weekend. IonQ dropped close to 2% on Friday. Rigetti Computing dipped around 2%, and Quantum Computing Inc. lost about 1.8%, highlighting just how sensitive the sector remains to risk.

Options pricing suggested more volatility ahead. According to a note from TheFly on TipRanks, implied volatility hovered near 100. Calls were trading more actively than puts, while the put-call skew grew steeper, indicating that some traders were willing to pay a premium for downside protection.

But the deal math works both ways. Should QBTS dip toward the collar’s lower bound, D-Wave will have to issue more shares to reach the $300 million stock value, upping dilution risk. If it holds steady, fewer shares get issued — yet the stock stays vulnerable to quick shifts in momentum trading.

Traders will zero in Monday on fresh details about the regulatory timeline and how the Quantum Circuits deal will wrap up. They’ll also look for clues on whether the company plans to raise capital to cover the $250 mln cash portion.

D-Wave’s Qubits 2026 conference on Jan. 27–28 is the next key date for investors, who will be scanning for details on the product roadmap and any progress on the gate-model strategy.

Stock Market Today

  • SpaceX IPO Filing Reveals Financials, Musk Could Become First Trillionaire
    May 20, 2026, 7:08 PM EDT. SpaceX filed for an initial public offering (IPO), disclosing its finances and board members for the first time. The company reported $18.7 billion in revenue for 2025, up 33% year-on-year, but posted a net loss of $4.9 billion, reversing a $791 million profit in 2024. First-quarter 2026 losses reached $4.3 billion on $4.7 billion revenue. The IPO, trading as SPCX, may become the largest ever, potentially boosting Elon Musk's wealth to trillionaire status. SpaceX aims to fund its ambitious plans including Starlink satellite network expansion, AI infrastructure, and establishing extraterrestrial colonies.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Rocket Companies stock jumps nearly 10% on Trump’s $200B mortgage-bond plan — what to watch next
Previous Story

Rocket Companies stock jumps nearly 10% on Trump’s $200B mortgage-bond plan — what to watch next

Tencent Holdings stock: buyback keeps pressure on bears as AI bottleneck warning hits tape
Next Story

Tencent Holdings stock: buyback keeps pressure on bears as AI bottleneck warning hits tape

Go toTop